Show simple item record

dc.contributor.authorLago Cooke, Santiago Guillermo
dc.date.accessioned2018-01-02T11:01:20Z
dc.date.available2018-01-02T11:01:20Z
dc.date.issued2016-10-07
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/270297
dc.description.abstractThe current work entails the development of a novel high content platform for the measurement of kinetic ligand responses across cell signalling networks at the single-cell level in distinct PBMC subtypes ex vivo. Using automated sample preparation, fluorescent cellular barcoding and flow cytometry the platform is capable of detecting 21, 840 parallel cell signalling responses in each PBMC sample. We apply this platform to characterize the effects of neuropsychiatric treatments and CNS ligands on the T cell signalling repertoire. We apply it to define cell signalling network abnormalities in PBMCs from drug-naïve first-onset schizophrenia patients (n=12) relative to healthy controls (n=12) which are subsequently normalized in PBMCs from the same patients (n=10) after a six week course of clinical treatment with the atypical antipsychotic olanzapine. We then validate the abnormal cell signalling responses in PBMCs from an independent cohort of drug-naïve first-onset schizophrenia patients (n=25) relative to controls (n=25) and investigate the specificity of the abnormal PBMC responses in schizophrenia as compared to major depression (n=25), bipolar disorder (n=25) and autism spectrum disorder (n=25). Subsequently we conduct a phenotypic drug screen using the US Food and Drug Administration (FDA) approved compound library, in addition to experimental neuropsychiatric drug candidates and nutraceuticals, to identify compounds which selectively normalize the schizophrenia-associated cell signalling response. Finally these candidate compounds are characterized using structure-activity relationships to reveal specific chemical moieties implicated in the putative therapeutic effect.
dc.description.sponsorshipEPSRC
dc.language.isoen
dc.rightsAll Rights Reserveden
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved/en
dc.subjectdrug discovery
dc.subjectneuropsychiatric disorders
dc.subjecthigh-content screening
dc.subjectsingle-cell
dc.subjectsignalling network
dc.titleA NOVEL PIPELINE FOR DRUG DISCOVERY IN NEUROPSYCHIATRIC DISORDERS USING HIGH-CONTENT SINGLE-CELL SCREENING OF SIGNALLING NETWORK RESPONSES EX VIVO
dc.typeThesis
dc.type.qualificationlevelDoctoral
dc.type.qualificationnameDoctor of Philosophy (PhD)
dc.publisher.institutionUniversity of Cambridge
dc.publisher.departmentChemical Engineering and Biotechnology
dc.date.updated2017-12-18T14:16:18Z
dc.identifier.doi10.17863/CAM.17148
dc.publisher.collegeDarwin
dc.type.qualificationtitlePhD
cam.supervisorBahn, Sabine
rioxxterms.freetoread.startdate2019-01-02


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record